schliessen

Filtern

 

Bibliotheken

Human papillomavirus and cervical cancer

Summary Cervical cancer is caused by human papillomavirus infection. Most human papillomavirus infection is harmless and clears spontaneously but persistent infection with high-risk human papillomavirus (especially type 16) can cause cancer of the cervix, vulva, vagina, anus, penis, and oropharynx.... Full description

Journal Title: The Lancet (British edition) 2013, Vol.382 (9895), p.889-899
Main Author: Crosbie, Emma J, PhD
Other Authors: Einstein, Mark H, MD , Franceschi, Silvia, MD , Kitchener, Henry C, Prof
Format: Electronic Article Electronic Article
Language: English
Subjects:
Age
Quelle: Alma/SFX Local Collection
Publisher: Kidlington: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1566834939
title: Human papillomavirus and cervical cancer
format: Article
creator:
  • Crosbie, Emma J, PhD
  • Einstein, Mark H, MD
  • Franceschi, Silvia, MD
  • Kitchener, Henry C, Prof
subjects:
  • Age
  • Anus
  • Biological and medical sciences
  • Cell Transformation, Neoplastic - pathology
  • Cell Transformation, Viral
  • Cellular biology
  • Cervical cancer
  • Cross-Sectional Studies
  • Developing Countries
  • Epidemiology
  • Female
  • Female genital diseases
  • General aspects
  • Gynecology. Andrology. Obstetrics
  • Human papillomavirus
  • Human papillomavirus 11 - immunology
  • Human papillomavirus 11 - pathogenicity
  • Human papillomavirus 11 - ultrastructure
  • Human papillomavirus 16
  • Human papillomavirus 16 - immunology
  • Human papillomavirus 16 - pathogenicity
  • Human papillomavirus 16 - ultrastructure
  • Human papillomavirus 18 - immunology
  • Human papillomavirus 18 - pathogenicity
  • Human papillomavirus 18 - ultrastructure
  • Human papillomavirus 6 - immunology
  • Human papillomavirus 6 - pathogenicity
  • Human papillomavirus 6 - ultrastructure
  • Humans
  • Immunization
  • Infectious diseases
  • Internal Medicine
  • Mass Screening
  • Medical sciences
  • Medical screening
  • Papillomavirus infections
  • Papillomavirus Infections - epidemiology
  • Papillomavirus Infections - immunology
  • Papillomavirus Infections - pathology
  • Papillomavirus Infections - prevention & control
  • Papillomavirus Infections - virology
  • Papillomavirus Vaccines - administration & dosage
  • Papillomavirus Vaccines - immunology
  • Papillomaviruses
  • Prevention
  • Properties
  • Risk factors
  • Studies
  • Tumors
  • Usage
  • Uterine Cervical Neoplasms - epidemiology
  • Uterine Cervical Neoplasms - immunology
  • Uterine Cervical Neoplasms - pathology
  • Uterine Cervical Neoplasms - prevention & control
  • Uterine Cervical Neoplasms - virology
  • Vaccines
  • Vaginal Smears
  • Viral diseases
  • Virus Replication
  • Womens health
ispartof: The Lancet (British edition), 2013, Vol.382 (9895), p.889-899
description: Summary Cervical cancer is caused by human papillomavirus infection. Most human papillomavirus infection is harmless and clears spontaneously but persistent infection with high-risk human papillomavirus (especially type 16) can cause cancer of the cervix, vulva, vagina, anus, penis, and oropharynx. The virus exclusively infects epithelium and produces new viral particles only in fully mature epithelial cells. Human papillomavirus disrupts normal cell-cycle control, promoting uncontrolled cell division and the accumulation of genetic damage. Two effective prophylactic vaccines composed of human papillomavirus type 16 and 18, and human papillomavirus type 16, 18, 6, and 11 virus-like particles have been introduced in many developed countries as a primary prevention strategy. Human papillomavirus testing is clinically valuable for secondary prevention in triaging low-grade cytology and as a test of cure after treatment. More sensitive than cytology, primary screening by human papillomavirus testing could enable screening intervals to be extended. If these prevention strategies can be implemented in developing countries, many thousands of lives could be saved.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.8150332
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1566834939
sourceformatXML
sourcesystemPC
galeidA343374026
sourcerecordidA343374026
originalsourceidFETCH-LOGICAL-1728t-357ae5b8112c4d46c0aff841649acbbd19ad4883293edc624b5898ad4520b4a03
addsrcrecordideNqNkmuL1DAUhoMo7rj6E5QBEUawa25NUgRlWdQVFvyggt9CmqZj1l7GnHZg_72nM-OOOwgjhbSE533JaR5CnjJ6xihTr79QJmmmtFALJl4qSjnP9D0yY1LLLJf6-30yu0VOyCOAa0qpVDR_SE64UMxgZkYWl2PruvnKrWLT9K1bxzTC3HXV3Ie0jt41c-86_H5MHtSugfBk9z4l3z68_3pxmV19_vjp4vwqY5qbIRO5diEvDWPcy0oqT11dG8mULJwvy4oVrpLGCF6IUHnFZZmbwuBezmkpHRWnZLHtXaX-1xhgsG0EH5rGdaEfwbJcKSNkIYrjqFSKFsJQ_h-oNJxRrhSizw_Q635MHc6MlKDSsFwXe2rpmmBjV_dDcn4qtedCCqElliF19g8Knyq00fddqCPu3wm8-itQjhC7ALhAXP4YYOlGgLt4vsV96gFSqO0qxdalG8uonTSxG03s5IBlwm40sRpzz3YzjmUbqtvUHy8QeLEDHKADdUIHIuw5rTT-Moncm4MD-Di4IfYdDhqbo8d4t00HFGodQ7LgY0DbqpiCH2zVx6MNbw8afBO7Sduf4SbA_uYscEu3JVMHE5sGLX4DHSj6Yw
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1430481579
display
typearticle
titleHuman papillomavirus and cervical cancer
sourceAlma/SFX Local Collection
creatorCrosbie, Emma J, PhD ; Einstein, Mark H, MD ; Franceschi, Silvia, MD ; Kitchener, Henry C, Prof
creatorcontribCrosbie, Emma J, PhD ; Einstein, Mark H, MD ; Franceschi, Silvia, MD ; Kitchener, Henry C, Prof
descriptionSummary Cervical cancer is caused by human papillomavirus infection. Most human papillomavirus infection is harmless and clears spontaneously but persistent infection with high-risk human papillomavirus (especially type 16) can cause cancer of the cervix, vulva, vagina, anus, penis, and oropharynx. The virus exclusively infects epithelium and produces new viral particles only in fully mature epithelial cells. Human papillomavirus disrupts normal cell-cycle control, promoting uncontrolled cell division and the accumulation of genetic damage. Two effective prophylactic vaccines composed of human papillomavirus type 16 and 18, and human papillomavirus type 16, 18, 6, and 11 virus-like particles have been introduced in many developed countries as a primary prevention strategy. Human papillomavirus testing is clinically valuable for secondary prevention in triaging low-grade cytology and as a test of cure after treatment. More sensitive than cytology, primary screening by human papillomavirus testing could enable screening intervals to be extended. If these prevention strategies can be implemented in developing countries, many thousands of lives could be saved.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(13)60022-7
3PMID: 23618600
4CODEN: LANCAO
languageeng
publisherKidlington: Elsevier Ltd
subjectAge ; Anus ; Biological and medical sciences ; Cell Transformation, Neoplastic - pathology ; Cell Transformation, Viral ; Cellular biology ; Cervical cancer ; Cross-Sectional Studies ; Developing Countries ; Epidemiology ; Female ; Female genital diseases ; General aspects ; Gynecology. Andrology. Obstetrics ; Human papillomavirus ; Human papillomavirus 11 - immunology ; Human papillomavirus 11 - pathogenicity ; Human papillomavirus 11 - ultrastructure ; Human papillomavirus 16 ; Human papillomavirus 16 - immunology ; Human papillomavirus 16 - pathogenicity ; Human papillomavirus 16 - ultrastructure ; Human papillomavirus 18 - immunology ; Human papillomavirus 18 - pathogenicity ; Human papillomavirus 18 - ultrastructure ; Human papillomavirus 6 - immunology ; Human papillomavirus 6 - pathogenicity ; Human papillomavirus 6 - ultrastructure ; Humans ; Immunization ; Infectious diseases ; Internal Medicine ; Mass Screening ; Medical sciences ; Medical screening ; Papillomavirus infections ; Papillomavirus Infections - epidemiology ; Papillomavirus Infections - immunology ; Papillomavirus Infections - pathology ; Papillomavirus Infections - prevention & control ; Papillomavirus Infections - virology ; Papillomavirus Vaccines - administration & dosage ; Papillomavirus Vaccines - immunology ; Papillomaviruses ; Prevention ; Properties ; Risk factors ; Studies ; Tumors ; Usage ; Uterine Cervical Neoplasms - epidemiology ; Uterine Cervical Neoplasms - immunology ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - prevention & control ; Uterine Cervical Neoplasms - virology ; Vaccines ; Vaginal Smears ; Viral diseases ; Virus Replication ; Womens health
ispartofThe Lancet (British edition), 2013, Vol.382 (9895), p.889-899
rights
0Elsevier Ltd
12013 Elsevier Ltd
22014 INIST-CNRS
3Copyright © 2013 Elsevier Ltd. All rights reserved.
4COPYRIGHT 2013 Elsevier B.V.
5Copyright Elsevier Limited Sep 7, 2013
lds50peer_reviewed
citedbyFETCH-LOGICAL-1728t-357ae5b8112c4d46c0aff841649acbbd19ad4883293edc624b5898ad4520b4a03
citesFETCH-LOGICAL-1728t-357ae5b8112c4d46c0aff841649acbbd19ad4883293edc624b5898ad4520b4a03
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27671444$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23618600$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Crosbie, Emma J, PhD
1Einstein, Mark H, MD
2Franceschi, Silvia, MD
3Kitchener, Henry C, Prof
title
0Human papillomavirus and cervical cancer
1The Lancet (British edition)
addtitleLancet
descriptionSummary Cervical cancer is caused by human papillomavirus infection. Most human papillomavirus infection is harmless and clears spontaneously but persistent infection with high-risk human papillomavirus (especially type 16) can cause cancer of the cervix, vulva, vagina, anus, penis, and oropharynx. The virus exclusively infects epithelium and produces new viral particles only in fully mature epithelial cells. Human papillomavirus disrupts normal cell-cycle control, promoting uncontrolled cell division and the accumulation of genetic damage. Two effective prophylactic vaccines composed of human papillomavirus type 16 and 18, and human papillomavirus type 16, 18, 6, and 11 virus-like particles have been introduced in many developed countries as a primary prevention strategy. Human papillomavirus testing is clinically valuable for secondary prevention in triaging low-grade cytology and as a test of cure after treatment. More sensitive than cytology, primary screening by human papillomavirus testing could enable screening intervals to be extended. If these prevention strategies can be implemented in developing countries, many thousands of lives could be saved.
subject
0Age
1Anus
2Biological and medical sciences
3Cell Transformation, Neoplastic - pathology
4Cell Transformation, Viral
5Cellular biology
6Cervical cancer
7Cross-Sectional Studies
8Developing Countries
9Epidemiology
10Female
11Female genital diseases
12General aspects
13Gynecology. Andrology. Obstetrics
14Human papillomavirus
15Human papillomavirus 11 - immunology
16Human papillomavirus 11 - pathogenicity
17Human papillomavirus 11 - ultrastructure
18Human papillomavirus 16
19Human papillomavirus 16 - immunology
20Human papillomavirus 16 - pathogenicity
21Human papillomavirus 16 - ultrastructure
22Human papillomavirus 18 - immunology
23Human papillomavirus 18 - pathogenicity
24Human papillomavirus 18 - ultrastructure
25Human papillomavirus 6 - immunology
26Human papillomavirus 6 - pathogenicity
27Human papillomavirus 6 - ultrastructure
28Humans
29Immunization
30Infectious diseases
31Internal Medicine
32Mass Screening
33Medical sciences
34Medical screening
35Papillomavirus infections
36Papillomavirus Infections - epidemiology
37Papillomavirus Infections - immunology
38Papillomavirus Infections - pathology
39Papillomavirus Infections - prevention & control
40Papillomavirus Infections - virology
41Papillomavirus Vaccines - administration & dosage
42Papillomavirus Vaccines - immunology
43Papillomaviruses
44Prevention
45Properties
46Risk factors
47Studies
48Tumors
49Usage
50Uterine Cervical Neoplasms - epidemiology
51Uterine Cervical Neoplasms - immunology
52Uterine Cervical Neoplasms - pathology
53Uterine Cervical Neoplasms - prevention & control
54Uterine Cervical Neoplasms - virology
55Vaccines
56Vaginal Smears
57Viral diseases
58Virus Replication
59Womens health
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2013
recordtypearticle
recordideNqNkmuL1DAUhoMo7rj6E5QBEUawa25NUgRlWdQVFvyggt9CmqZj1l7GnHZg_72nM-OOOwgjhbSE533JaR5CnjJ6xihTr79QJmmmtFALJl4qSjnP9D0yY1LLLJf6-30yu0VOyCOAa0qpVDR_SE64UMxgZkYWl2PruvnKrWLT9K1bxzTC3HXV3Ie0jt41c-86_H5MHtSugfBk9z4l3z68_3pxmV19_vjp4vwqY5qbIRO5diEvDWPcy0oqT11dG8mULJwvy4oVrpLGCF6IUHnFZZmbwuBezmkpHRWnZLHtXaX-1xhgsG0EH5rGdaEfwbJcKSNkIYrjqFSKFsJQ_h-oNJxRrhSizw_Q635MHc6MlKDSsFwXe2rpmmBjV_dDcn4qtedCCqElliF19g8Knyq00fddqCPu3wm8-itQjhC7ALhAXP4YYOlGgLt4vsV96gFSqO0qxdalG8uonTSxG03s5IBlwm40sRpzz3YzjmUbqtvUHy8QeLEDHKADdUIHIuw5rTT-Moncm4MD-Di4IfYdDhqbo8d4t00HFGodQ7LgY0DbqpiCH2zVx6MNbw8afBO7Sduf4SbA_uYscEu3JVMHE5sGLX4DHSj6Yw
startdate2013
enddate2013
creator
0Crosbie, Emma J, PhD
1Einstein, Mark H, MD
2Franceschi, Silvia, MD
3Kitchener, Henry C, Prof
general
0Elsevier Ltd
1Elsevier
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
100TT
110TZ
120U~
133V.
147QL
157QP
167RV
177TK
187U7
197U9
207X7
217XB
2288A
2388C
2488E
2588G
2688I
278AF
288AO
298C1
308C2
318FE
328FH
338FI
348FJ
358FK
368G5
37ABUWG
38AN0
39ASE
40AZQEC
41BBNVY
42BEC
43BENPR
44BHPHI
45C1K
46DWQXO
47FPQ
48FYUFA
49GHDGH
50GNUQQ
51GUQSH
52H94
53HCIFZ
54K6X
55K9-
56K9.
57KB0
58KB~
59LK8
60M0R
61M0S
62M0T
63M1P
64M2M
65M2O
66M2P
67M7N
68M7P
69MBDVC
70NAPCQ
71PQEST
72PQQKQ
73PQUKI
74Q9U
75S0X
sort
creationdate2013
titleHuman papillomavirus and cervical cancer
authorCrosbie, Emma J, PhD ; Einstein, Mark H, MD ; Franceschi, Silvia, MD ; Kitchener, Henry C, Prof
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1728t-357ae5b8112c4d46c0aff841649acbbd19ad4883293edc624b5898ad4520b4a03
rsrctypearticles
prefilterarticles
languageeng
creationdate2013
topic
0Age
1Anus
2Biological and medical sciences
3Cell Transformation, Neoplastic - pathology
4Cell Transformation, Viral
5Cellular biology
6Cervical cancer
7Cross-Sectional Studies
8Developing Countries
9Epidemiology
10Female
11Female genital diseases
12General aspects
13Gynecology. Andrology. Obstetrics
14Human papillomavirus
15Human papillomavirus 11 - immunology
16Human papillomavirus 11 - pathogenicity
17Human papillomavirus 11 - ultrastructure
18Human papillomavirus 16
19Human papillomavirus 16 - immunology
20Human papillomavirus 16 - pathogenicity
21Human papillomavirus 16 - ultrastructure
22Human papillomavirus 18 - immunology
23Human papillomavirus 18 - pathogenicity
24Human papillomavirus 18 - ultrastructure
25Human papillomavirus 6 - immunology
26Human papillomavirus 6 - pathogenicity
27Human papillomavirus 6 - ultrastructure
28Humans
29Immunization
30Infectious diseases
31Internal Medicine
32Mass Screening
33Medical sciences
34Medical screening
35Papillomavirus infections
36Papillomavirus Infections - epidemiology
37Papillomavirus Infections - immunology
38Papillomavirus Infections - pathology
39Papillomavirus Infections - prevention & control
40Papillomavirus Infections - virology
41Papillomavirus Vaccines - administration & dosage
42Papillomavirus Vaccines - immunology
43Papillomaviruses
44Prevention
45Properties
46Risk factors
47Studies
48Tumors
49Usage
50Uterine Cervical Neoplasms - epidemiology
51Uterine Cervical Neoplasms - immunology
52Uterine Cervical Neoplasms - pathology
53Uterine Cervical Neoplasms - prevention & control
54Uterine Cervical Neoplasms - virology
55Vaccines
56Vaginal Smears
57Viral diseases
58Virus Replication
59Womens health
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Crosbie, Emma J, PhD
1Einstein, Mark H, MD
2Franceschi, Silvia, MD
3Kitchener, Henry C, Prof
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9News PRO
10Pharma and Biotech Premium PRO
11Global News & ABI/Inform Professional
12ProQuest Central (Corporate)
13Bacteriology Abstracts (Microbiology B)
14Calcium & Calcified Tissue Abstracts
15Nursing & Allied Health Database
16Neurosciences Abstracts
17Toxicology Abstracts
18Virology and AIDS Abstracts
19Health & Medical Collection
20ProQuest Central (purchase pre-March 2016)
21Biology Database (Alumni Edition)
22Healthcare Administration Database (Alumni)
23Medical Database (Alumni Edition)
24Psychology Database (Alumni)
25Science Database (Alumni Edition)
26STEM Database
27ProQuest Pharma Collection
28Public Health Database
29Lancet Titles
30ProQuest SciTech Collection
31ProQuest Natural Science Collection
32Hospital Premium Collection
33Hospital Premium Collection (Alumni Edition)
34ProQuest Central (Alumni) (purchase pre-March 2016)
35Research Library (Alumni Edition)
36ProQuest Central (Alumni Edition)
37British Nursing Database
38British Nursing Index
39ProQuest Central Essentials
40Biological Science Collection
41eLibrary
42ProQuest Central
43Natural Science Collection
44Environmental Sciences and Pollution Management
45ProQuest Central Korea
46British Nursing Index (BNI) (1985 to Present)
47Health Research Premium Collection
48Health Research Premium Collection (Alumni)
49ProQuest Central Student
50Research Library Prep
51AIDS and Cancer Research Abstracts
52SciTech Premium Collection
53British Nursing Index
54Consumer Health Database (Alumni Edition)
55ProQuest Health & Medical Complete (Alumni)
56Nursing & Allied Health Database (Alumni Edition)
57ProQuest Newsstand Professional
58ProQuest Biological Science Collection
59Consumer Health Database
60Health & Medical Collection (Alumni Edition)
61Healthcare Administration Database
62Medical Database
63Psychology Database
64Research Library
65Science Database
66Algology Mycology and Protozoology Abstracts (Microbiology C)
67Biological Science Database
68Research Library (Corporate)
69Nursing & Allied Health Premium
70ProQuest One Academic Eastern Edition
71ProQuest One Academic
72ProQuest One Academic UKI Edition
73ProQuest Central Basic
74SIRS Editorial
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Crosbie, Emma J, PhD
1Einstein, Mark H, MD
2Franceschi, Silvia, MD
3Kitchener, Henry C, Prof
formatjournal
genrearticle
ristypeJOUR
atitleHuman papillomavirus and cervical cancer
jtitleThe Lancet (British edition)
addtitleLancet
date2013
risdate2013
volume382
issue9895
spage889
epage899
pages889-899
issn0140-6736
eissn1474-547X
codenLANCAO
abstractSummary Cervical cancer is caused by human papillomavirus infection. Most human papillomavirus infection is harmless and clears spontaneously but persistent infection with high-risk human papillomavirus (especially type 16) can cause cancer of the cervix, vulva, vagina, anus, penis, and oropharynx. The virus exclusively infects epithelium and produces new viral particles only in fully mature epithelial cells. Human papillomavirus disrupts normal cell-cycle control, promoting uncontrolled cell division and the accumulation of genetic damage. Two effective prophylactic vaccines composed of human papillomavirus type 16 and 18, and human papillomavirus type 16, 18, 6, and 11 virus-like particles have been introduced in many developed countries as a primary prevention strategy. Human papillomavirus testing is clinically valuable for secondary prevention in triaging low-grade cytology and as a test of cure after treatment. More sensitive than cytology, primary screening by human papillomavirus testing could enable screening intervals to be extended. If these prevention strategies can be implemented in developing countries, many thousands of lives could be saved.
copKidlington
pubElsevier Ltd
pmid23618600
doi10.1016/S0140-6736(13)60022-7